Literature DB >> 27734083

Triple Antithrombotic Therapy and Outcomes in Post-PCI Patients Undergoing Non-cardiac Surgery.

Javier A Valle1,2, Laura Graham3, Aerin DeRussy3, Kamal Itani4, Mary T Hawn5, Thomas M Maddox6.   

Abstract

BACKGROUND: Triple therapy, or the use of anticoagulants with dual antiplatelet therapy (DAPT), is often used to protect against ischemic events in post-percutaneous coronary intervention (PCI) patients with indications for anticoagulation, but is associated with increased bleeding. As both ischemic and bleeding risks increase in the perioperative period, the impact of triple therapy may be especially pronounced in patients undergoing surgery. Outcomes in this population are currently unknown.
METHODS: We identified patients undergoing non-cardiac surgeries within 2 years of PCI in Veterans Affairs hospitals from 2004 to 2012. We compared perioperative major adverse cardiovascular and cerebrovascular events (MACCE: mortality, myocardial infarction, stroke, revascularization) and bleeding events (in-hospital bleeding, transfusion) between surgeries in patients prescribed triple therapy and DAPT, adjusting for clinical, demographic, and operative characteristics.
RESULTS: Among 7811 surgeries, 391 (5.0 %) occurred in patients receiving triple therapy. 44 (11.3 %) MACCE and 107 (27.4 %) bleeding events occurred with surgeries in triple therapy patients, compared to 366 (4.9 %) MACCE and 980 (13.2 %) bleeding events in DAPT patients. After adjustment, surgery in triple therapy patients was associated with higher rates of MACCE [odds ratio (OR) 1.65, 95 % confidence interval (CI) 1.16-2.34] or bleeding (OR 1.52, 95 % CI 1.17-1.99) as compared to surgery in DAPT patients.
CONCLUSIONS: One in twenty post-PCI patients undergoing non-cardiac surgery were on triple therapy. Surgery in these patients was associated with higher MACCE and bleeding events compared to surgery in patients on DAPT, independent of clinical and operative characteristics. These findings identify a high-risk population for surgery, which may warrant increased surveillance for adverse perioperative events.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 27734083     DOI: 10.1007/s00268-016-3725-5

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  35 in total

1.  Informatics resources to support health care quality improvement in the veterans health administration.

Authors:  Denise M Hynes; Ruth A Perrin; Steven Rappaport; Joanne M Stevens; John G Demakis
Journal:  J Am Med Inform Assoc       Date:  2004-06-07       Impact factor: 4.497

2.  Improving quality measurement for anticoagulation: adding international normalized ratio variability to percent time in therapeutic range.

Authors:  Zayd Razouki; Al Ozonoff; Shibei Zhao; Guneet K Jasuja; Adam J Rose
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2014-09-02

3.  Concomitant use of antiplatelet therapy with dabigatran or warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial.

Authors:  Antonio L Dans; Stuart J Connolly; Lars Wallentin; Sean Yang; Juliet Nakamya; Martina Brueckmann; Michael Ezekowitz; Jonas Oldgren; John W Eikelboom; Paul A Reilly; Salim Yusuf
Journal:  Circulation       Date:  2012-12-27       Impact factor: 29.690

4.  Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial.

Authors:  Willem J M Dewilde; Tom Oirbans; Freek W A Verheugt; Johannes C Kelder; Bart J G L De Smet; Jean-Paul Herrman; Tom Adriaenssens; Mathias Vrolix; Antonius A C M Heestermans; Marije M Vis; Jan G P Tijsen; Arnoud W van 't Hof; Jurriën M ten Berg
Journal:  Lancet       Date:  2013-02-13       Impact factor: 79.321

5.  Perioperative Bridging Anticoagulation in Patients with Atrial Fibrillation.

Authors:  James D Douketis; Alex C Spyropoulos; Scott Kaatz; Richard C Becker; Joseph A Caprini; Andrew S Dunn; David A Garcia; Alan Jacobson; Amir K Jaffer; David F Kong; Sam Schulman; Alexander G G Turpie; Vic Hasselblad; Thomas L Ortel
Journal:  N Engl J Med       Date:  2015-06-22       Impact factor: 91.245

6.  Triple therapy with aspirin, prasugrel, and vitamin K antagonists in patients with drug-eluting stent implantation and an indication for oral anticoagulation.

Authors:  Nikolaus Sarafoff; Amadea Martischnig; Jill Wealer; Katharina Mayer; Julinda Mehilli; Dirk Sibbing; Adnan Kastrati
Journal:  J Am Coll Cardiol       Date:  2013-03-21       Impact factor: 24.094

7.  Anticoagulant and antiplatelet therapy use in 426 patients with atrial fibrillation undergoing percutaneous coronary intervention and stent implantation implications for bleeding risk and prognosis.

Authors:  Juan M Ruiz-Nodar; Francisco Marín; José Antonio Hurtado; José Valencia; Eduardo Pinar; Javier Pineda; Juan Ramón Gimeno; Francisco Sogorb; Mariano Valdés; Gregory Y H Lip
Journal:  J Am Coll Cardiol       Date:  2008-02-26       Impact factor: 24.094

8.  Risk of major adverse cardiac events following noncardiac surgery in patients with coronary stents.

Authors:  Mary T Hawn; Laura A Graham; Joshua S Richman; Kamal M F Itani; William G Henderson; Thomas M Maddox
Journal:  JAMA       Date:  2013-10-09       Impact factor: 56.272

Review 9.  Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary intervention/ stenting.

Authors:  Gregory Y H Lip; Kurt Huber; Felicita Andreotti; Harald Arnesen; K Juhani Airaksinen; Thomas Cuisset; Paulus Kirchhof; Francisco Marín
Journal:  Thromb Haemost       Date:  2009-09-30       Impact factor: 5.249

10.  Bleeding after initiation of multiple antithrombotic drugs, including triple therapy, in atrial fibrillation patients following myocardial infarction and coronary intervention: a nationwide cohort study.

Authors:  Morten Lamberts; Jonas Bjerring Olesen; Martin Huth Ruwald; Carolina Malta Hansen; Deniz Karasoy; Søren Lund Kristensen; Lars Køber; Christian Torp-Pedersen; Gunnar Hilmar Gislason; Morten Lock Hansen
Journal:  Circulation       Date:  2012-08-06       Impact factor: 29.690

View more
  2 in total

1.  Lycium barbarum polysaccharides inhibit ischemia/reperfusion-induced myocardial injury via the Nrf2 antioxidant pathway.

Authors:  Jin-Jun Liu; Gong-Xiao Zhao; Lei-Lei He; Zheng Wang; Abdoulaye Issotina Zibrila; Bai-Chun Niu; Hao-Yu Gong; Jing-Ning Xu; Lynn Soong; Chun-Fang Li; Yi Lu
Journal:  Toxicol Rep       Date:  2021-03-24

2.  Dual versus single antiplatelet therapy for patients with long-term oral anticoagulation undergoing coronary intervention: a systematic review and meta-analysis.

Authors:  Jing-Jing Yu; Chan Zou; Wen-Yu Liu; Guo-Ping Yang
Journal:  J Geriatr Cardiol       Date:  2017-12       Impact factor: 3.327

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.